Kroger stock falls after Amazon announces major grocery expansion
Kevin Joseph Fitzgerald, Chief Scientific Officer and Executive Vice President at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently sold a portion of his common stock holdings in the company. According to the SEC filing, Fitzgerald sold a total of 496 shares on February 28, 2025, generating proceeds of approximately $119,877. The shares were sold at prices ranging from $236.51 to $244.11. The transaction comes as Alnylam, now valued at $31.4 billion, has delivered an impressive 61.7% return over the past year. According to InvestingPro analysis, the stock is currently trading near its Fair Value.
Following these transactions, Fitzgerald holds a direct ownership of 12,385 shares of Alnylam Pharmaceuticals. Additionally, he has an indirect ownership of 537 shares through a managed account, as part of the company’s 401(k) matching contribution program. The sales were executed to cover minimum statutory tax withholding obligations related to the vesting of restricted stock units. While analyst targets range from $195 to $500, InvestingPro subscribers can access 8 additional key insights about Alnylam’s financial health and growth prospects, along with a comprehensive Pro Research Report available for this and 1,400+ other US stocks.
In other recent news, Alnylam Pharmaceuticals has been the focus of several analyst updates and pipeline developments. H.C. Wainwright increased its price target for Alnylam to $500 while maintaining a Buy rating, highlighting the potential of AMVUTTRA and nucresiran in treating transthyretin-mediated diseases. Alnylam reported fourth-quarter earnings that aligned with preliminary figures, projecting net product revenues for 2025 between $2.05 billion and $2.25 billion. RBC Capital reiterated its Outperform rating with a $310 target, emphasizing Alnylam’s robust R&D pipeline and the upcoming Prescription Drug User Fee Act (PDUFA) date. Piper Sandler maintained an Overweight rating with a $304 target, anticipating the approval of AMVUTTRA for ATTR-CM treatment by March 2025, which could boost sales to $2.75 billion by 2026.
Canaccord Genuity slightly raised its price target to $385, maintaining a Buy rating, and noted the attention on Amvuttra’s potential label expansion for ATTR-CM. The company is preparing for the launch of AMVUTTRA with a PDUFA date set for March 23, 2025. Alnylam is also advancing its central nervous system-targeted pipeline, including treatments for Alzheimer’s and Huntington’s diseases. Additionally, the company has revealed new targets for obesity and type 2 diabetes, with early-stage projects progressing. These developments underscore Alnylam’s strategic positioning and potential in RNA interference therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.